12:00 AM
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Jentadueto linagliptin/metformin regulatory update

EMA's CHMP issued a positive opinion recommending approval of an MAA from Boehringer for Jentadueto linagliptin/metformin to treat Type II diabetes. Boehringer and partner Eli Lilly market...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >